The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
about
Translating pharmacogenomics: challenges on the road to the clinicPersonalized medicine: hope or hype?CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosingWarfarin: almost 60 years old and still causing problemsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenetics and anaesthesia: the value of genetic profilingInfluence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisBiomarkers for strokePharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonPharmacogenetics-based warfarin dosing in childrenEffects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinEffect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysisThe c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patientsApproaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric populationWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsTherapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north IndiansVirtual Pharmacist: A Platform for PharmacogenomicsA New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish PopulationNetwork-based drug discovery by integrating systems biology and computational technologiesAn acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiationIncreased rodenticide exposure rate and risk of toxicosis in barn owls (Tyto alba) from southwestern Canada and linkage with demographic but not genetic factors.Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.Estimation of the warfarin dose with clinical and pharmacogenetic data.Integration of genetic, clinical, and INR data to refine warfarin dosing.Warfarin pharmacogenomicsRisk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.Screening for 392 polymorphisms in 141 pharmacogenes.The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population.Warfarin therapy: in need of improvement after all these years.High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testingImplementing genotype-guided antithrombotic therapy.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Warfarin and vitamin K intake in the era of pharmacogenetics.Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patientsA pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.
P2860
Q21092371-113D4D3E-8FD1-4F1F-96A3-5901F278C314Q24289193-7C2ED04F-0E3D-4CCB-9A10-9976B84920CCQ24641999-0FB66798-1334-46D1-AA96-8CB881A46E01Q24678632-D505985D-6E61-4B6D-8795-D0178357DD78Q26823542-CB2F9327-395B-49C1-9D94-5F5C023D3AC5Q26859221-27A16459-1576-4795-8366-4DA74AC6882BQ27002899-20200431-1BD8-4BEC-A0D7-AE189386A109Q27004404-AFE2B857-1D79-4A35-B439-DF66E4182C7AQ27006860-229995F4-A0CE-4243-9F83-6349C185C7ECQ27008320-EFAF7E26-8968-42A7-87A7-27AABE5C0618Q27026134-72DA90EB-9258-4DF3-902B-0CAF1BE2B46BQ28276514-76D5389D-2585-46B3-92D9-E242E1F0A5D4Q28276605-F7E6D843-8A15-44A7-A85A-7CF9A7580AB3Q28306899-139D634D-7765-414B-BAA4-3A0A60F48C86Q28389663-7B218BE2-571C-4CF2-AAE7-560AB053DEDBQ28395337-5E7174A8-4B5F-4D77-B2E4-A41FCE88F473Q28483861-E96338F0-FC7E-49F8-A926-E35534D7F043Q28550464-E538145D-A3E5-45E1-8CB2-902C5974190AQ28550740-5F1785B4-8788-4267-BB1B-7353A0DE1B86Q28677268-C6B8BAE3-C297-4879-A8A3-459A4DABAA5FQ30558676-647ED691-C0D2-4B14-8A0C-54C898E45233Q31042226-CF593190-E3A2-4B5B-8F26-458A3F90143EQ31091877-A4B2BDFC-B8E8-4C3D-8648-62DB9224F482Q33311569-F5FC7BE2-6CB2-4C8E-8F7F-EB3DF8849B46Q33410725-42215179-8C26-4BA7-9D23-58C6475271E3Q33550741-AFB1546C-3642-4F3D-AAE1-9B7452DE0992Q33561482-A50A03A5-7072-4C60-8004-2CBABE66BC2CQ33680181-3725F9C0-8D57-48B7-8FA6-48DF2BE3C1EEQ33733501-C2B10CFD-82D2-46F7-8EBE-F7906FADA9BAQ33782314-CE847FD3-C74D-459F-807B-24863E80DC8AQ33793086-52339444-239B-4F75-ABAE-984358112593Q33802999-D9E19B8E-82FC-4351-BA4D-69DF2DF94F1EQ33813830-09E749FF-B828-4E39-80DC-083036206713Q33990428-9FFF5D1C-8A4D-4738-B1ED-B3F27DD325E3Q33990441-C52ECB7B-8323-42D8-B1FE-942C83E45527Q34026225-A77276B2-40F5-4F81-838D-C482BC386DC7Q34042341-0EA96A75-6B38-4405-BFCE-65E1B05550CDQ34050936-69FAAAA0-886B-45CA-9FDD-2110C8128A6EQ34061511-F55F9430-E2CF-4E14-BCAF-9583670CE563Q34065133-A88ECC1B-16D4-4BDA-B0A3-CA873B5CD0E8
P2860
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The impact of CYP2C9 and VKORC ...... osal for a new dosing regimen.
@en
The impact of CYP2C9 and VKORC ...... osal for a new dosing regimen.
@nl
type
label
The impact of CYP2C9 and VKORC ...... osal for a new dosing regimen.
@en
The impact of CYP2C9 and VKORC ...... osal for a new dosing regimen.
@nl
prefLabel
The impact of CYP2C9 and VKORC ...... osal for a new dosing regimen.
@en
The impact of CYP2C9 and VKORC ...... osal for a new dosing regimen.
@nl
P2093
P1433
P1476
The impact of CYP2C9 and VKORC ...... osal for a new dosing regimen.
@en
P2093
Barry P King
Elizabeth A Sconce
Farhad Kamali
Hilary A Wynne
Louise Monkhouse
Patrick Kesteven
Peter Avery
Peter Wood
Tayyaba I Khan
P304
P356
10.1182/BLOOD-2005-03-1108
P407
P50
P577
2005-06-09T00:00:00Z